Technical Analysis for RCKT - Rocket Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 20.76 -3.22% -0.69
RCKT closed down 3.22 percent on Friday, January 17, 2020, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical RCKT trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup -3.22%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.22%
NR7 Range Contraction -3.22%
Stochastic Reached Oversold Weakness -3.22%
Inside Day Range Contraction -3.22%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.
Medicine Biotechnology Medical Specialties Heart Failure Anemia University Of California Genetic Disorder Fanconi Anemia Pyruvate Kinase Deficiency

Is RCKT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 27.59
52 Week Low 10.76
Average Volume 401,275
200-Day Moving Average 15.90
50-Day Moving Average 20.13
20-Day Moving Average 22.94
10-Day Moving Average 22.68
Average True Range 1.39
ADX 32.13
+DI 22.13
-DI 23.38
Chandelier Exit (Long, 3 ATRs ) 21.16
Chandelier Exit (Short, 3 ATRs ) 24.75
Upper Bollinger Band 24.94
Lower Bollinger Band 20.94
Percent B (%b) -0.05
BandWidth 17.42
MACD Line 0.38
MACD Signal Line 0.89
MACD Histogram -0.5062
Fundamentals Value
Market Cap 560.77 Million
Num Shares 27 Million
EPS -1.53
Price-to-Earnings (P/E) Ratio -13.57
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.50
Resistance 3 (R3) 22.63 22.19 22.21
Resistance 2 (R2) 22.19 21.74 22.12 22.11
Resistance 1 (R1) 21.47 21.47 21.25 21.34 22.02
Pivot Point 21.03 21.03 20.92 20.96 21.03
Support 1 (S1) 20.31 20.58 20.09 20.18 19.50
Support 2 (S2) 19.87 20.31 19.80 19.41
Support 3 (S3) 19.15 19.87 19.31
Support 4 (S4) 19.02